Therefore, dasatinib, an inhibitor of Src kinase activity, can effectively reduce Ets1 protein and significantly suppress the development of metastatic and invasive cisplatin-resistant head and neck squamous cell carcinoma[16]. The gene discussed is ETS1; the disease is head and neck squamous cell carcinoma.